Read More

Mizuho Remains Bullish On This Small-Cap Stock’s Migraine Candidate, But Why Did It Cut Price Target

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine. 

IMPL

Read More

Impel NeuroPharma Earnings Preview

Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Impel NeuroPharma will report an earnings per share (EPS) of $-1.05.

IMPL

Read More

Benzinga’s After-Hours Movers & News: Williams-Sonoma, PagerDuty And More

Benzinga’s “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's Movers tool. Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks.

ASPN